Amyloid-associated cystic lung disease in primary Sjögren's syndrome  by Baqir, Misbah et al.
Respiratory Medicine (2013) 107, 616e621Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate /rmedAmyloid-associated cystic lung disease
in primary Sjo¨gren’s syndromeMisbah Baqir a, Elizabeth M. Kluka a, Marie-Christine Aubry c,
Thomas E. Hartman b, Eunhee S. Yi c, Philippe R. Bauer a,
Jay H. Ryu a,*aDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA
bDepartment of Radiology, Mayo Clinic, Rochester, MN, USA
cDivision of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA
Received 20 August 2012; accepted 10 January 2013
Available online 10 February 2013KEYWORDS
Amyloidosis;
Cystic lung disease;
Sjogren’s syndromeAbbreviations: FISH, fluorescence in si
amyloid A; SAP, serum amyloid P; SS,
* Corresponding author. Division of
MN 55905, USA. Tel.: þ1 507 284 2447
E-mail addresses: baqir.misbah@
(M.-C. Aubry), hartman.thomas@ma
ryu.jay@mayo.edu (J.H. Ryu).
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.20Summary
Background: Cystic lung disease can be seen in patients with Sjo¨gren’s syndrome (SS) and is
generally thought to be due to lymphocytic interstitial pneumonia.
Methods: Using computer-assisted search we identified patients with primary SS seen at Mayo
Clinic, Rochester, MN during a 14-year period from 1997 to 2010 who were diagnosed with pulmo-
nary amyloidosis confirmed on lung biopsy. Clinical records, imaging studies, and pathologic spec-
imenswere reviewed to delineate presenting features, diagnostic evaluation, and clinical course.
Results: Eight patients (7 women, 1 man) with primary SS were diagnosed with pulmonary
amyloidosis by lung biopsy (7 surgical, 1 bronchoscopic). Their median age was 55 years (range,
32e75 years) and all were nonsmokers. Presenting symptoms included dyspnea and cough but 4
patients presentedwith radiologic abnormalities in the absence of respiratory symptoms. CT find-
ings included cystic lesions and nodular opacities in all eight patients. PET scan performed in six
patients did not reveal 18F-2-deoxyglucose (FDG) uptake except in one nodulewith borderline up-
take. Lung biopsy demonstrated the presence of amyloid in all patients and was associated with
mucosa-associated lymphoid tissue (MALT) lymphoma in three patients. Pulmonary function re-
sultswere normal in five patients and revealedmild impairment in amixed pattern in one patient.
Conclusions: We conclude cystic and nodular lung lesions seen in patients with primary SS can
represent amyloidosis which can be associated with MALT lymphoma in some of these patients.
ª 2013 Elsevier Ltd. All rights reserved.tu hybridization; H & E, hematoxylin and eosin; MALT, mucosa-associated lymphoid tissue; SAA, serum
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honeycombing (<5 mm, 6e10 mm, 11e20 mm and >20 mm)Sjo¨gren’s syndrome (SS) is a chronic inflammatory disorder
characterized by lymphocytic infiltration of exocrine glands
resulting in xerostomia, keratoconjunctivitis sicca, and
parotid gland enlargement.1e4 Primary SS is distinguished
from secondary SS by the absence of an underlying rheu-
matic condition, e.g., rheumatoid arthritis, and affects
3%e4% of the adult population, primarily women.5 Primary
SS is associated with diverse extraglandular manifestations
involving the skin, kidney, lung as well as the vascular and
nervous systems.4,6
Several pulmonary manifestations can be encountered in
patients with primary SS. These include interstitial lung dis-
ease, airway disease, lymphoproliferative disease, pleural
disease, and, rarely, pulmonary vascular abnormalities.7e9
Cystic lung disease in patients with SS has been usually
associated with lymphocytic interstitial pneumonia and fol-
licular bronchiolitis but amyloidosis has occasionally been
implicated.8,10e13 In this study we sought to clarify the rela-
tionship between pulmonary amyloidosis and cystic lung
disease in patients with primary SS.
Patients and methods
A computer-assisted search of medical records was con-
ducted and identified 8 subjects with primary SS seen
at Mayo Clinic, Rochester, MN during a 14-year-period
between Jan. 1, 1997 and Dec. 31, 2010. Approval was
obtained from the Mayo Foundation Institutional Review
Board prior to beginning the study.
All subjects included in this study fulfilled the current
consensus criteria for primary SS.1 We identified those who
had pulmonary amyloidosis diagnosed on bronchoscopic or
surgical lung biopsy and had relevant chest imaging studies
available for review. Medical records of these patients were
reviewed to extract data regarding age, sex, smoking his-
tory, clinical presentation, imaging studies, biopsy pro-
cedures, and diagnoses.
The chest imaging studies were reviewed by two expe-
rienced readers (TEH, JHR) independently and were eval-
uated for pulmonary, pleural and mediastinal/hilar
abnormalities. The pulmonary abnormalities evaluated
included: nodules, reticular opacities, interlobular septal
thickening, ground-glass opacities, consolidation, cysts,
honeycombing and emphysema. If expiratory images were
available, they were evaluated for the presence of air-
trapping. When nodules were present they were evaluated
for number (solitary, 2e10 and >10), attenuation (solid,
semisolid and ground-glass), margins (smooth and irregu-
lar), extent (<10%, 10e40% and >40%), lung distribution
(unilateral, bilateral asymmetric and bilateral symmetric),
axial distribution (central, subpleural and perilymphatic)
and cephalocaudal distribution (upper, lower and diffuse).
When reticular opacities, interlobular septal thickening,
ground-glass opacities, consolidation or emphysema were
present they were evaluated for extent, lung distribution,
axial distribution and cephalocaudal distribution as out-
lined above. When cysts and honeycombing were present
they were evaluated for extent, lung distribution, axial
distribution and cephalocaudal distribution as outlinedabove. Additional note was made on the size of the cysts or
based on the predominate size of the cysts or honey-
combing. Mediastinal/hilar images evaluated were primar-
ily evaluated for adenopathy, but any other abnormalities
noted were recorded. Adenopathy was present if the short
axis diameter of a node was >10 mm. Differences in
interpretation were settled by consensus.
Pathology specimens were available for current review
in five patients, including four wedge biopsies and one
transbronchial biopsy. The pathologic information was
abstracted from the pathology reports in the other three
patients whose wedge biopsies were obtained at another
institution and were previously reviewed by us during their
clinical evaluation at Mayo Clinic. Hematoxylin and eosin
(H & E) and Congo red staining was performed in all cases.
Immunohistochemical studies for lymphoma work-up was
performed in 7 patients and included antibodies directed
against CD3 and CD20 in 7, with kappa and lambda immu-
noglobulin light chains in 6, and fluorescence in situ
hybridization (FISH) for kappa and lambda light chains in
one. Immunohistochemistry for amyloid battery including
serum amyloid P (SAP) component, serum amyloid A (SAA)
protein, transthyretin, beta-2 microglobulin, kappa and
lambda immunoglobulin light chains, was performed in two
patients and liquid chromatography tandem mass spec-
trometry in another five. The focus of the histologic review
was on the identification of cysts and cause as highlighted
by radiologic findings in these patients.
Results
Clinical and laboratory features
Eight patients (seven women, one man) with primary SS
were diagnosed with pulmonary amyloidosis by lung biopsy
(seven surgical, one bronchoscopic) (Table 1). Their median
age was 55 years (range, 32e75 years). Presenting symp-
toms included dyspnea and cough in four patients and four
remaining patients presented with incidental abnormalities
noted on chest imaging without respiratory symptoms. All
eight patients had sicca symptoms with two patients having
enlarged parotid glands.
All patients manifested anti-SS-A/Ro and anti-SS-B/La
antibodies. Serum protein electrophoresis revealed biclonal
gammopathy in one patient (75F patient on Table 1) but
was negative in the remaining seven patients including
urine protein electrophoresis that had been performed in
five of these seven patients. One symptomatic patient with
extensive nodular and cystic lesions (56F on Table 1) was
treated rituximab therapy but no specific therapy for
amyloidosis or MALT lymphoma was undertaken for the
remaining seven patients.
Chest imaging
Chest radiography was abnormal in seven patients and
revealed nodular or interstitial opacities but was normal in
the remaining patient. Cystic lesions were identified by
chest radiography in two of eight patients. Chest CT scan-
ning revealed parenchymal cysts in all eight patients
Table 1 Characteristics of eight patients with primary Sjogren’s syndrome and pulmonary amyloidosis.
Age (yr),
gender
Smoking Respiratory
symptoms
Pulmonary
function
Chest CT FDG-PET Type of
lung biopsy
Pathologic
findings
56F Never Dyspnea,
cough
Obstructive
& restrictive
>10 cysts, >10 nodules NA Surgical Amyloid,
lymphoid
hyperplasia
74F Never Dyspnea Normal 2 cysts, 2 nodules No uptake Surgical Amyloid, MALToma
48F Never Dyspnea Normal >10 Cysts, >10 nodules NA Surgical Amyloid, MALToma
53F Never None Normal >10 cysts, >10 nodules Borderline
uptake
Surgical Amyloid, MALToma
75F Never None Normal >10 cysts, >10 nodule No uptake Bronchoscopic Amyloid
32F Never None Normal >10 cysts, >10 nodule No uptake Surgical Amyloid
58F Never None NA 1 cysts, 7 nodules No uptake Surgical Amyloid
39M Never Cough Normal >10 cysts, 7 nodules No uptake Surgical Amyloid,
follicular
bronchiolitis
Abbreviations: F Z female, M Z male, FDG-PET Z fluorodeoxyglucose 18F positron emission tomography, NA Z data not available.
618 M. Baqir et al.(Fig. 1). In six cases the cysts were bilateral and asym-
metric and in two cases the cysts were unilateral. In the
unilateral cases, one had only one cyst and the other had
only two cysts. In the six bilateral cases, four had lower
lung predominance and in two cases the cysts were diffuse.
With regard to axial distribution, the cysts were diffuse
without a subpleural, central or perilymphatic distribution.
In one case the predominant cyst size was <5 mm, in 4
cases the predominant size was 6e10 mm and in 3 cases the
predominant size was 11e20 mm.
Chest CT scan also revealed two or more nodules in all
eight patients (Fig. 2). In four patients the nodules were of
mixed attenuation containing solid, semisolid and/or
ground glass components. In four remaining cases, only
solid nodules were present. The pulmonary nodules varied
in size from less than 5 mm to greater than 10 mm; one of
the nodules was cavitated. In one case, several of the
larger nodules were partially calcified. The nodule distri-
bution was bilateral and asymmetric in all eight patients
with lower lung predominance in five.Figure 1 CT scan of the chest of a 48-year-old woman,
nonsmoker, with primary Sjogren’s syndrome and MALT type
lymphoma with associated amyloid deposition in the lung.
There are multiple cystic lesions bilaterally.Ground-glass opacities were seen in two cases. In both
cases, there was a solitary area of ground glass attenuation
that involved <10% of the lung. No cases had reticular
opacities, interlobular septal thickening, consolidation,
honeycombing or emphysema. Additionally, no cases had
pleural abnormalities or adenopathy.
On follow-up CT of the four cases with solid nodules, in
one case the nodules were stable; in the second case one
nodule had cavitated, one had decreased and the rest were
stable; in the third case, one had increased and the rest
were stable; and in the fourth case, the nodules had
increased in number and size over the interval of 68
months. Of the four cases with mixed nodules, one had
a decrease in size and number over the long term, but had
a mixed response on early follow-up. In the second case,
the solid nodules increased or were stable and the semi-
solid nodules were stable. In the third case, there was
a mixed response, with no overall change. In the fourth
case, all nodules were stable. The cavity that was seen on
the initial CT in one case had become solid. Of the eightFigure 2 CT scan of the chest of a 32-year-old woman,
nonsmoker, with primary Sjogren’s syndrome nodular pulmo-
nary amyloidosis. Several nodules measuring 5 mme22 mm are
present.
Figure 4 Cystically dilated spaces surrounded by dense
lymphoid infiltrates (hematoxylin and eosin staining,
40 original magnification).
Cystic amyloid lung disease in Sjo¨gren’s 619cases with cysts, one had new cysts develop. Of the pre-
viously noted cysts, in six cases the cysts were stable and in
two cases the cyst size increased. In the two cases with
ground-glass opacities, one was stable and one decreased.
In no case did a nodule become a cyst even with the longest
followup of 99 months.
PET scan was performed in six patients for assessment of
pulmonary nodules and did not reveal 18F-2-deoxyglucose
(FDG) uptake except in one nodule with borderline activity
(maximal standardized uptake value [SUVmax] 2.2)
(Table 1). Pulmonary function results were available in six
patients and revealed normal results except mild impair-
ment in a mixed pattern in one patient.
Histopathological findings
The presence of amyloid was confirmed on lung biopsies of
all eight patients with Congo red staining (Fig. 3) and by
immmunohistochemistry or mass spectrometry was deter-
mined as AL-kappa type in seven. In three patients amyloid
was associated with mucosa-associated lymphoid tissue
(MALT) lymphoma, two with kappa light chain restriction
and one with lambda light chain restriction in the plasma
cells (Figs. 4e6). The amyloid subtype was not specifically
assessed in the patient with the lambda light chain re-
striction in the MALT lymphoma. Of the five patients with-
out MALT lymphoma, follicular bronchiolitis and lymphoid
hyperplasia were seen in one patient each while the
remaining three patients exhibited amyloid only. The latter
group included the patient who was diagnosed by bron-
choscopic lung biopsy that demonstrated only amyloid and
bronchoalveolar lavage showed no lymphocytes.
Of the seven patients with wedge biopsies, the presence
of cysts was recorded in five and identified on histologic
review in three, one with lymphoid hyperplasia and two
with MALT lymphoma. In one patient, the cyst walls were
comprised of the lymphoid infiltrate while for the other
two, a mixture of both the lymphoid infiltrate and amyloid.
In two of these cases, the cysts appeared to be dilatedFigure 3 Confluent deposition of eosinophilic amorphous
materials in the right half of the field (hematoxylin and eosin,
200), consistent with amyloid that is supported by sulfated
Alcian blue staining (inset, 200).airways involved by the amyloid. None of the biopsies
showed findings characteristic of lymphocytic interstitial
pneumonia, i.e., diffuse infiltration of alveolar septa by
lymphocytes and plasma cells. In all cases, the nodules
could be explained by the amyloid with or without an
associated lymphoid infiltrate.Discussion
In this study of patients with primary SS, we found pulmo-
nary amyloidosis to be associated with cystic lesions and
nodules. The association of cysts in the lung with amyloid is
of particular interest since pulmonary cysts in patients with
SS are generally assumed to be due to lymphocytic inter-
stitial pneumonia and not biopsied. In addition, we found
MALToma to be present in nearly one-half of these primary
SS patients with pulmonary amyloid.Figure 5 Markedly increased B-lymphocytes within the lym-
phoid infiltrates (anti-CD20 immunostaining, 400). These
B-cells are kappa light-chain-restricted by immunohistochem-
ical method (not shown).
Figure 6 Diffusely present plasma cells within the lymphoid
infiltrates (anti-CD138 immunostaining, 400). These B-cells
are kappa light-chain-restricted by immunohistochemical
method (not shown).
620 M. Baqir et al.Sjogren Syndrome is a chronic inflammatory disorder but
is also recognized as a lymphoproliferative disease with
varying presentation from polyclonal lymphocytic infiltra-
tion of the salivary glands to oligo- or monoclonal B cell
proliferation resulting in clonally derived lymphoprolifer-
ative disorders such as monoclonal gammopathy, light-chain
amyloidosis, and malignant lymphoma.14,15 Pulmonary
involvement in primary SS is being increasingly recognized
and can present with parenchymal, pleural, airway or vas-
cular manifestations.9,16e18 Amyloid deposition in patients
with SS is less well known but has been described to occur in
multiple organs including the skin,19,20 kidney,21 breast,22
tongue,23 lymph nodes,24 as well as the lung.9,25e28
All of our eight patients with SS and pulmonary amyloi-
dosis presented with cysts and nodules on chest imaging
and all of them had AL type amyloid. AL amyloidosis in SS
has most often been reported as localized nodular pulmo-
nary amyloidosis.29,30 For example, Desai and colleagues30
described three patients who manifested lung nodules
and cysts associated with pulmonary amyloidosis; two of
these patients had SS. Amyloid deposition was believed to
be related to the benign lymphoproliferative process seen
in the lung. Lantejoul and colleagues12 reported cystic and
nodular lung lesions in a patient with amyloidosis asso-
ciated with MALT lymphoma but without SS. It appears that
cystic lung lesions can be seen with amyloidosis in the
presence or absence of SS or MALT lymphoma.
The mechanism of cyst formation is not fully under-
stood. Some authors have proposed the presence of in-
flammatory cells or amyloid exhibiting ball-valve
mechanism resulting from bronchiolar obstruction.28 In
support of this theory Jeong et al.29 described histopatho-
logic findings in a patient with SS-related pulmonary amy-
loidosis and cystic lung disease in whom the cyst appeared
to be located distal to bronchioles narrowed by amyloid
deposition and lymphoproliferative cell infiltration, they
were also able to demonstrate that the cysts were lined
with bronchiolar epithelial cells rather than alveolar epi-
thelium. Another proposed mechanism for cyst formation is
the fragility and destruction of alveolar walls due tointerstitial inflammation. Colombat et al.31 have shown the
role of metalloproteinases released by macrophages caus-
ing elastolysis and cystic lung diseases in pulmonary light
chain deposition disease. Additional studies analyzing
larger lung specimens such as those obtained at autopsy or
explants may yield clarification on how cysts form. Multiple
mechanisms may lead to development of cystic lung lesions
in patients with pulmonary amyloidosis associated with SS.
FDG uptake on PET scanning has been described in iso-
lated cases of amyloidosis.32,33 In contrast, FDG uptake is
seen in the majority of MALT lymphomas but depends partly
on the underlying histologic features of the tumor.34e36 In
six of our patients who underwent PET scanning no FGD
uptake was seen in the lung with the exception of on nodule
that exhibited borderline FDG uptake in a patient with
pulmonary MALToma.
There are several limitations to our study including the
retrospective design and a modest number of study sub-
jects. In addition, there was limited follow-up data on the
clinical course of these patients. Additional studies are
needed to define the long-term evolution of cystic and
nodular pulmonary lesions as well as the associated prog-
nosis in SS patients with pulmonary amyloidosis.
In summary, we conclude that cystic and nodular lung
lesions in patients with primary SS can represent pulmonary
amyloidosis with or without MALT-type lymphoma. Clini-
cians need to be aware of diverse causes of cystic lung
lesions in patients with SS.Disclosure
None for all authors.
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